Antibody-Drug Conjugates in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A historical overview of treatment advances for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and the rationale for treating appropriate patients with an approved antibody-drug conjugate therapy.

Potential implications for treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with loncastuximab tesirine, an antibody-drug conjugate, based on early results demonstrated by the LOTIS-2 study.

Recommendations for mitigating and managing common treatment-related adverse events associated with loncastuximab tesirine based on safety data from LOTIS-2 and variables that may impact patient candidacy.

Tycel Jovelle Phillips, MD, of the University of Michigan, comments on his preferences for treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and shares his expectations for sequencing with newer, novel approaches emerging in the field.

Tycel Jovelle Phillips, MD, reviews current therapy options for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and how he selects among these options and highlights some potential new therapies.